SEATTLE — Dr. Jay Evans has spent over 20 years building vaccines. The director of the Center for Translational Medicine at the University of Washington School of Medicine has worked on shots for influenza and tuberculosis. Now he has turned that expertise toward a fundamentally different target: fentanyl.
The figure that matters: a novel vaccine candidate against fentanyl and its analogs. Evans and his team published their study in Nature Communications in 2024.
The work represents a shift in how researchers think about addiction treatment — moving from behavioral interventions and replacement therapies toward immunological prevention. Here is the bottom line. The vaccine uses a hapten-based approach.
That means scientists attach a small molecule — in this case, a fentanyl-like compound — to a larger carrier protein. The immune system learns to recognize the opioid as an invader.
If a vaccinated person later takes fentanyl, antibodies bind to the drug before it can reach the brain and produce a high. By the numbers, this is a broad-spectrum strategy. Evans’ research focuses on creating vaccines that work not just against fentanyl itself but against its analogs — the chemically similar synthetic opioids that dealers often substitute or mix in.
That matters because the illicit drug supply is unpredictable. A vaccine that only blocks one variant would leave users vulnerable to others. Investors will note the funding sources.
Evans has received support from the National Institutes of Health and the Defense Advanced Research Projects Agency. DARPA’s interest signals potential military applications — protecting soldiers from accidental exposure or from incapacitating agents.
The NIH backing underscores the public health urgency. Dr. Evans holds a Ph.D. in immunology. His publication record includes papers in top peer-reviewed journals, with the fentanyl vaccine appearing specifically in Nature Communications.
The research builds on decades of work in hapten-based vaccine design, a field that has previously produced vaccines against nicotine and cocaine in clinical trials. The mechanism is precise.
When someone injects or ingests fentanyl, the drug normally crosses the blood-brain barrier quickly and binds to opioid receptors. That binding triggers euphoria, respiratory depression, and — at high enough doses — death. The vaccine-induced antibodies intercept fentanyl in the bloodstream before it can cross into the brain.
No brain entry means no high, and no respiratory arrest. The challenge is durability. Hapten-based vaccines require careful design to provoke a strong enough antibody response.
The immune system does not naturally recognize small molecules like fentanyl as threats. The carrier protein tricks it into doing so.
Evans’ team had to optimize that pairing to produce high-affinity antibodies that could neutralize the drug at realistic blood concentrations. Seattle is the base of operations. The University of Washington School of Medicine’s Center for Translational Medicine sits at the intersection of lab science and clinical application.
Evans directs that center, meaning his work moves from bench research toward human trials. The timeline matters.
The study appeared in 2024. The research has advanced through preclinical stages. Human clinical trials would be the next step, though no specific trial start date has been announced.
The regulatory pathway for an addiction vaccine is not straightforward — the FDA has never approved a vaccine for substance use disorder. What to watch next. If the vaccine enters human trials, researchers will need to measure antibody titers, duration of protection, and whether vaccinated individuals simply switch to non-opioid drugs.
There is also the question of uptake: a vaccine works only if people choose to get it. That requires a healthcare infrastructure capable of delivering shots to the population most at risk.
Dr. Evans’ broader research program continues. The same hapten-based platform could apply to other synthetic opioids, to stimulants, or to novel psychoactive substances as they emerge. The approach is modular.
Change the hapten, keep the carrier, and the immune system can learn to attack a new target. For now, the data lives in peer-reviewed literature.
The Nature Communications paper provides the evidence base. The funding from NIH and DARPA provides the resources. The center in Seattle provides the institutional home. Consult your doctor for medical advice.
{“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Dr. Jay Evans Leads Fight Against Fentanyl Analogs with Vaccine Innovation”, “description”: “SEATTLE — Dr. Jay Evans has spent over 20 years building vaccines. The director of the Center for Translational Medicine at the University of Washington…”, “datePublished”: “2026-07-13T09:30:00+00:00”, “author”: {“@type”: “Person”, “name”: “Ava Anderson”}, “publisher”: {“@type”: “Organization”, “name”: “InfoPulse Today”, “url”: “https://newsfeed.infopulsetoday.com/”}}
